These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 26939703)
1. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759 [TBL] [Abstract][Full Text] [Related]
3. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma. Kamiya T; Chang YH; Campana D Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065 [TBL] [Abstract][Full Text] [Related]
4. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096 [TBL] [Abstract][Full Text] [Related]
5. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype. Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib with ASC-J9 Xu J; Lin H; Li G; Sun Y; Shi L; Ma WL; Chen J; Cai X; Chang C Int J Cancer; 2017 Feb; 140(3):705-717. PubMed ID: 27668844 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039 [TBL] [Abstract][Full Text] [Related]
13. MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3. Su Z; Ye X; Shang L Yonsei Med J; 2019 Jan; 60(1):22-29. PubMed ID: 30554487 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959 [TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356 [TBL] [Abstract][Full Text] [Related]
16. RAC1 Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407 [TBL] [Abstract][Full Text] [Related]
17. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. Wang SH; Yeh SH; Shiau CW; Chen KF; Lin WH; Tsai TF; Teng YC; Chen DS; Chen PJ J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26206949 [TBL] [Abstract][Full Text] [Related]
19. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]